Advanced Rheumatology of Houston | Houston, TX

Research site

(Unclaimed)

Location

10857 Kuykendahl Road Suite 160, The Woodlands, Texas, United States of America

Site insights

Top conditions

Top treatments

Litifilimab

Dazodalibep

Baricitinib

BIIB059

Apremilast

Olokizumab

Guselkumab

Adalimumab

Upadacitinib

Tofacitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 15 total trials

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

Enrolling

Sjögren's Syndrome

Drug: Dazodalibep

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Enrolling

Sjögren's Syndrome (SS)

Drug: Dazodalibep

Drug: Placebo

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting

Psoriatic Arthritis

Biological: Placebo

Biological: Risankizumab

Status recently updated

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-1)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling

Active, not recruiting

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Litifilimab

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's (EnVISage)

This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to backgroun...

Enrolling

Sjogren Disease

Biological: Sibeprenlimab

Other: Placebo

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (EMERALD)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Invitation-only

Systemic Lupus Erythematosus (SLE)

Drug: Litifilimab-matching placebo

Drug: Litifilimab

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Active, not recruiting

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Active, not recruiting

Rheumatoid Arthritis

Drug: Adalimumab

Drug: Upadacitinib